Author

J. Raymenants

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Assay:bulk RNA-seq· 1 Organism:human· 1 Assay:imaging· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

E. Andre· 3 shared P. Maes· 3 shared B. Slechten· 2 shared J. Neyts· 2 shared A. Seve· 1 shared B. Vanmechelen· 1 shared B. Weynand· 1 shared C. Geenen· 1 shared

Activity by Year

2021-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

E. Andre

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.

L. Vangeel, W. Chiu, S. De Jonghe, P. Maes, B. Slechten, J. Raymenants, E. Andre, P. Leyssen, J. Neyts, D. Jochmans

The paper evaluates the antiviral activity of remdesivir, molnupiravir, and nirmatrelvir against SARS-CoV-2 variants, finding they remain effective.

bioRxiv · Dec 27, 2021Microbiology

The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters

R. Abdelnabi, C. S.-Y. Foo, X. Zhang, V. Lemmens, P. Maes, B. Slechten, J. Raymenants, E. Andre, B. Weynand, K. Dallmeier, J. Neyts

This study shows that the omicron SARS-CoV-2 variant infects Syrian hamsters with significantly lower viral loads in the lungs compared to the D614G strain, with no detectable infectious virus.

bioRxiv · Dec 24, 2021Microbiology

Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization

D. Planas, N. Saunders, P. Maes, F. G. Benhassine, C. Planchais, F. Porrot, I. Staropoli, F. Lemoine, H. Pere, D. Veyer, J. Puech, J. Rodary, W. H. Bolland, J. Buchrieser, G. Baele, , O. Schwartz

This study shows that the Omicron variant of SARS-CoV-2 is resistant to most monoclonal antibodies and vaccine-induced antibodies, with reduced neutralization compared to Delta.

bioRxiv · Dec 14, 2021Immunology